Bertrand Chauveau
Overview
Explore the profile of Bertrand Chauveau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sablik M, Sannier A, Raynaud M, Goutaudier V, Divard G, Astor B, et al.
N Engl J Med
. 2024 Oct;
392(8):763-776.
PMID: 39450752
Background: The heterogeneous clinical presentation of graft microvascular inflammation poses a major challenge to successful kidney transplantation. The effect of microvascular inflammation on allograft outcomes is unclear. Methods: We conducted...
2.
Chauveau B, Couzi L, Merville P
Transplantation
. 2024 Oct;
109(3):440-453.
PMID: 39436268
The Banff classification is regularly updated to integrate recent advances in the characterization of kidney allograft rejection, gathering novel diagnostic, prognostic, and theragnostic data into a diagnostic and pathogenesis-based framework....
3.
Kamar N, Bertrand D, Caillard S, Pievani D, Apithy M, Congy-Jolivet N, et al.
Kidney Int Rep
. 2024 Oct;
9(10):2927-2936.
PMID: 39430184
Introduction: Imlifidase is authorized for desensitization of highly sensitized adult kidney transplant candidates with a positive crossmatch (XM) against a deceased donor. Here, we report on the results for the...
4.
Chauveau B, Gibier J, Rabant M
Am J Kidney Dis
. 2024 Apr;
84(1):129.
PMID: 38604266
No abstract available.
5.
Chauveau B, Burguet L, Merville P
J Nephrol
. 2024 Mar;
37(4):1177-1179.
PMID: 38530602
No abstract available.
6.
Chauveau B, Gibier J, Olagne J, Morel A, Aydin S, McAdoo S, et al.
Am J Kidney Dis
. 2024 Jan;
83(6):713-728.e1.
PMID: 38171412
Rationale & Objective: Atypical anti-glomerular basement membrane (GBM) nephritis is characterized by a bright linear immunoglobulin staining along the GBM by immunofluorescence without a diffuse crescentic glomerulonephritis nor serum anti-GBM...
7.
Chambord J, Chauveau B, Djabarouti S, Vignaud J, Taton B, Moreau K, et al.
Transpl Int
. 2023 Dec;
36:11962.
PMID: 38089004
Our objective was to calculate an immunosuppressant possession ratio (IPR) to diagnose non-adherence at the time of antibody-mediated rejection (ABMR). IPR was defined as the ratio of number of pills...
8.
9.
Noelle J, Mayet V, Lambert C, Couzi L, Chauveau B, Thierry A, et al.
Transpl Int
. 2023 Oct;
36:11775.
PMID: 37799669
The impact of immunosuppressive therapy (IS) strategies after kidney transplant failure (KTF) on potential future new grafts is poorly established. We assessed the potential benefit of calcineurin inhibitor (CNI)-based IS...
10.
Pfirmann P, Garrigue I, Chauveau B, Rondeau V, Tumiotto C, Weinmann L, et al.
Nephrol Dial Transplant
. 2023 Sep;
39(4):627-636.
PMID: 37667539
Background: While opportunistic infections are a frequent and challenging problem in kidney transplant recipients, their long-term epidemiology remains hardly known. Methods: Opportunistic infections were recorded in 1144 recipients transplanted in...